Risk factors of isoniazid mono-resistance among pulmonary tuberculosis patients at Central Chest Institute of Thailand
2
Issued Date
2019
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
Faculty of Pharmacy Mahidol University
Suggested Citation
Phenlak Kaewthong, Pramote Tragulpiankit, Chareon Chuchottaworn, Sukanya Wattanapokayakit, Suppanut Prakongsup, Nuanjun Wichukchinda, Surakameth Mahasirimongkol (2019). Risk factors of isoniazid mono-resistance among pulmonary tuberculosis patients at Central Chest Institute of Thailand. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/49690
Title
Risk factors of isoniazid mono-resistance among pulmonary tuberculosis patients at Central Chest Institute of Thailand
Abstract
Isoniazid is the most important drug for tuberculosis treatment. Risk factors of isoniazid
mono-resistance were reported by N-acetyltransferase 2 (NAT2) gene and some clinical factors
in the literature. This study aimed to determine the risk factors of isoniazid mono-resistance
among Thai pulmonary tuberculosis patients. The case-control study was conducted from 18th
September 2017 to 20th February 2018. Demographic data were collected from medical record
review and patient interview. NAT2 genotypes were collected from saliva samples collection.
Risk factors were conducted by multivariate logistic regression analysis and strength of
association was reported as odd ratio with 95% confident interval. Total 167 participants
comprised of 50 isoniazid mono-resistant and 117 drug-susceptible tuberculosis patients.
NAT2*4/*6A was the most common genotype in both 12 (24.0%) cases and 38 (32.5%)
controls, respectively, and there was not significantly different among genotypes between two
groups (p-value = 0.352). Moreover, rapid acetylator was not significantly associated with
isoniazid mono-resistance compared with slow acetylator (OR 1.169; 95%CI 0.435-3.140, pvalue
= 0.389). Adults who were less than 50 years old were more likely to develop isoniazid
mono-resistance (adjusted OR 2.281; 95%CI 1.101-4.728, p-value = 0.027) than elderlys who
were older than 50 years old. In contrast, ever-drinkers were less likely to develop isoniazid
mono-resistance (adjusted OR 0.417; 95%CI 0.207-0.842, p-value = 0.015). In conclusion, the
young adults and never-drinkers are risk factors of isoniazid mono-resistance in these Thai
pulmonary tuberculosis patients. Moreover, a further study is needed to clarify the role of NAT2
on isoniazid mono-resistance in Thais.
Description
The 1st Pharmaceutical Sciences Asia Conference 2019 Theme : Pharmaceutical Sciences toward Health Innovation in the Disruptive Era. Bangkok Midtown Hotel, Thailand. August 22, 2019, page 33